West Pharmaceutical Services (WST) Expected to Announce Quarterly Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is expected to be issuing its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect the company to announce earnings of $1.68 per share and revenue of $779.6750 million for the quarter. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, April 23, 2026 at 8:00 AM ET.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.21. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The business had revenue of $805.00 million during the quarter, compared to analysts’ expectations of $795.70 million. During the same quarter in the prior year, the firm earned $1.82 earnings per share. The business’s revenue was up 7.5% compared to the same quarter last year. On average, analysts expect West Pharmaceutical Services to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

West Pharmaceutical Services Price Performance

Shares of West Pharmaceutical Services stock opened at $275.10 on Wednesday. The business has a 50 day simple moving average of $250.12 and a two-hundred day simple moving average of $261.68. West Pharmaceutical Services has a 12 month low of $199.89 and a 12 month high of $322.34. The stock has a market capitalization of $19.83 billion, a P/E ratio of 40.52, a PEG ratio of 2.96 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.02 and a quick ratio of 2.34.

West Pharmaceutical Services declared that its Board of Directors has approved a share repurchase plan on Tuesday, February 17th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical instruments supplier to buy up to 5.6% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be issued a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, April 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is presently 12.96%.

Wall Street Analysts Forecast Growth

WST has been the subject of a number of research analyst reports. Barclays increased their target price on West Pharmaceutical Services from $265.00 to $275.00 and gave the company an “equal weight” rating in a report on Tuesday, April 14th. UBS Group reissued a “buy” rating and set a $340.00 target price on shares of West Pharmaceutical Services in a report on Friday, February 13th. Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a report on Friday, February 13th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $295.00 price target on shares of West Pharmaceutical Services in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and an average price target of $315.67.

Institutional Investors Weigh In On West Pharmaceutical Services

Large investors have recently made changes to their positions in the stock. CYBER HORNET ETFs LLC purchased a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $25,000. DV Equities LLC purchased a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $28,000. MUFG Securities EMEA plc purchased a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $47,000. State of Wyoming purchased a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $49,000. Finally, Meeder Asset Management Inc. grew its position in shares of West Pharmaceutical Services by 1,023.5% in the fourth quarter. Meeder Asset Management Inc. now owns 191 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 174 shares in the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.